Terms: = Lung cancer AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Clinical Outcome
6 results:
1. New application of an old drug: Antitumor activity and mechanisms of doxycycline in small cell lung cancer.
Wang SQ; Zhao BX; Liu Y; Wang YT; Liang QY; Cai Y; Zhang YQ; Yang JH; Song ZH; Li GF
Int J Oncol; 2016 Apr; 48(4):1353-60. PubMed ID: 26846275
[TBL] [Abstract] [Full Text] [Related]
2. timp-1 overexpression in lung carcinoma enhances tumor kinetics and angiogenesis in brain metastasis.
Rojiani MV; Ghoshal-Gupta S; Kutiyanawalla A; Mathur S; Rojiani AM
J Neuropathol Exp Neurol; 2015 Apr; 74(4):293-304. PubMed ID: 25756591
[TBL] [Abstract] [Full Text] [Related]
3. Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC.
Blumenschein GR; Reck M; Fossella F; Stewart DJ; Lathia C; Peña C
Cancer Biomark; 2011-2012; 10(6):287-98. PubMed ID: 22820084
[TBL] [Abstract] [Full Text] [Related]
4. Identification of potential lung cancer biomarkers using an in vitro carcinogenesis model.
Kim JE; Koo KH; Kim YH; Sohn J; Park YG
Exp Mol Med; 2008 Dec; 40(6):709-20. PubMed ID: 19116456
[TBL] [Abstract] [Full Text] [Related]
5. MMP-2, timp-2 and CD44v6 expression in non-small-cell lung carcinomas.
Eren B; Sar M; Oz B; Dincbas FH
Ann Acad Med Singap; 2008 Jan; 37(1):32-9. PubMed ID: 18265895
[TBL] [Abstract] [Full Text] [Related]
6. Biological and clinical significance of MMP-2, MMP-9, timp-1 and timp-2 in non-small cell lung cancer.
Iniesta P; Morán A; De Juan C; Gómez A; Hernando F; García-Aranda C; Frías C; Díaz-López A; Rodríguez-Jiménez FJ; Balibrea JL; Benito M
Oncol Rep; 2007 Jan; 17(1):217-23. PubMed ID: 17143501
[TBL] [Abstract] [Full Text] [Related]
